Relationship of Age at First Live Birth, Parity and Duration of Breast Feeding with Non Familial Breast Cancer in Pakistani Women. A Study of the Cancer Research Group Pakistan

被引：0
作者：
Ahmad, S.
Mahmood, H.
Kanwal, S.
Mahmood, A.
Ahmad, K.
Masood, M.
Faheem, M.
Akbar, N.
Hafeez, M.
机构：
[1] King Edward Med Univ, Lahore, Pakistan
[2] Nucl Med Oncol Radiotherapy Inst, Islamabad, Pakistan
[3] Combined Mil Hosp, Rawalpindi, Pakistan
[4] Inst Nucl Med & Oncol, Lahore, Pakistan
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
Breast Cancer; Breast feeding; Parity; Risk Factor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：616S / 616S
页数：1
相关论文
共 37 条
  • [31] FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)
    Aristides Polyzos
    Nikolaos Malamos
    Ioannis Boukovinas
    Adamos Adamou
    Nikolaos Ziras
    Kostas Kalbakis
    Stylianos Kakolyris
    Kostas Syrigos
    Pavlos Papakotoulas
    Charalambos Kouroussis
    Nikolaos Karvounis
    Lambros Vamvakas
    Charalambos Christophyllakis
    Athanasios Athanasiadis
    Ioannis Varthalitis
    Vassilis Georgoulias
    Dimitris Mavroudis
    Breast Cancer Research and Treatment, 2010, 119 : 95 - 104
  • [32] FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG)
    Polyzos, Aristides
    Malamos, Nikolaos
    Boukovinas, Ioannis
    Adamou, Adamos
    Ziras, Nikolaos
    Kalbakis, Kostas
    Kakolyris, Stylianos
    Syrigos, Kostas
    Papakotoulas, Pavlos
    Kouroussis, Charalambos
    Karvounis, Nikolaos
    Vamvakas, Lambros
    Christophyllakis, Charalambos
    Athanasiadis, Athanasios
    Varthalitis, Ioannis
    Georgoulias, Vassilis
    Mavroudis, Dimitris
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 95 - 104
  • [33] Longitudinal Assessment of Physical Activity, Fitness, Body Composition, Immunological Biomarkers, and Psychological Parameters During the First Year After Diagnosis in Women With Non-Metastatic Breast Cancer: The BEGYN Study Protocol
    Zemlin, Cosima
    Stuhlert, Caroline
    Schleicher, Julia Theresa
    Woermann, Carolin
    Altmayer, Laura
    Lang, Marina
    Scherer, Laura-Sophie
    Thul, Ida Clara
    Mueller, Carolin
    Kaiser, Elisabeth
    Stutz, Regine
    Goedicke-Fritz, Sybelle
    Ketter, Laura
    Zemlin, Michael
    Wagenpfeil, Gudrun
    Steffgen, Georges
    Solomayer, Erich-Franz
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
    Mavroudis, D.
    Saloustros, E.
    Malamos, N.
    Kakolyris, S.
    Boukovinas, I.
    Papakotoulas, P.
    Kentepozidis, N.
    Ziras, N.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1333 - 1340
  • [35] Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
    Mavroudis, D.
    Matikas, A.
    Malamos, N.
    Papakotoulas, P.
    Kakolyris, S.
    Boukovinas, I.
    Athanasiadis, A.
    Kentepozidis, N.
    Ziras, N.
    Katsaounis, P.
    Saloustros, E.
    Georgoulias, V.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1873 - 1878
  • [36] Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer:: results of the double-blind cross-over SAKK trial 21/95 -: a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial
    Thürlimann, B
    Hess, D
    Köberle, D
    Senn, I
    Ballabeni, P
    Pagani, O
    Perey, L
    Aebi, S
    Rochlitz, C
    Goldhirsch, A
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 85 (03) : 247 - 254
  • [37] Anastrozole (‘Arimidex’) versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: Results of the double-blind cross-over SAKK trial 21/95 - a sub-study of the TARGET (Tamoxifen or ‘Arimidex’ Randomized Group Efficacy and Tolerability) trial
    Beat Thürlimann
    Dagmar Hess
    Dieter Köberle
    Isabella Senn
    Pierluigi Ballabeni
    Olivia Pagani
    Lucien Perey
    Stefan Aebi
    Christoph Rochlitz
    Aron Goldhirsch
    Breast Cancer Research and Treatment, 2004, 85 : 247 - 254
1234